Renalytix Plc announced that Timothy Scannell has been appointed to the Board as an independent Non-Executive Director of Renalytix. As an accomplished leader in healthcare innovation, Mr. Scannell brings more than 30 years of experience in medical technology to the Renalytix Board, and previously served as President and C.O.O. of Stryker. Mr. Scannell currently serves as Chair of Insulet Corporation's board of directors and serves on the board of directors for Novocure and Collagen Matrix.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
27.5 GBX | 0.00% | -8.33% | +77.42% |
Apr. 18 | Renalytix chief business officer to become president | AN |
Apr. 18 | Renalytix Names Chief Business Officer as President | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+77.42% | 43.64M | |
-45.18% | 2.7B | |
+15.62% | 1.83B | |
-2.14% | 1.63B | |
+21.24% | 1.2B | |
-13.27% | 995M | |
-21.67% | 896M | |
-6.04% | 726M | |
-15.76% | 701M | |
+14.15% | 527M |
- Stock Market
- Equities
- RENX Stock
- News Renalytix Plc
- Renalytix plc Appoints Timothy Scannell as Independent Non-Executive Director